New hope for psoriasis patients when standard treatments fail
NCT ID NCT06945107
First seen Apr 07, 2026 · Last updated May 07, 2026 · Updated 3 times
Summary
This study tests a new medicine called picankibart for people with plaque psoriasis who did not get good results from standard IL-17 antibody treatments. About 310 adults in China will receive either picankibart or an active control to see if switching helps clear skin and reduce symptoms. The trial lasts 48 weeks and focuses on safety and how well the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatology Hospital of Shandong First Medical University (Shandong Provincial Hospitial of Dermatology)
Jinan, Shandong, 250000, China
Conditions
Explore the condition pages connected to this study.